The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Ibrutinib treatment before apheresis improves CAR-T therapy results in R/R DLBCL patients
Julio Chavez, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, discusses the initial results of a Phase Ib study aiming to evaluate the efficacy of ibrutinib treatment prior to and after apheresis in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients undergoing tisagenlecleucel (tisa-cel) therapy. The findings suggested that prior treatment with ibrutinib has a tolerable safety profile and may lead to an improvement in CAR-T cell quality and concentration in R/R DLCBL patients treated with tisa-cel. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
